R&D This week in clinical trials: 2nd-5th January 2024 Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.